JP2013543491A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543491A5
JP2013543491A5 JP2013530571A JP2013530571A JP2013543491A5 JP 2013543491 A5 JP2013543491 A5 JP 2013543491A5 JP 2013530571 A JP2013530571 A JP 2013530571A JP 2013530571 A JP2013530571 A JP 2013530571A JP 2013543491 A5 JP2013543491 A5 JP 2013543491A5
Authority
JP
Japan
Prior art keywords
medicament
medicament according
administered
compound
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013530571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050375 external-priority patent/WO2012041334A1/en
Publication of JP2013543491A publication Critical patent/JP2013543491A/ja
Publication of JP2013543491A5 publication Critical patent/JP2013543491A5/ja
Pending legal-status Critical Current

Links

JP2013530571A 2010-10-01 2011-09-30 急性外傷性凝固障害及び蘇生した心停止の予防または処置に使用するための血管内皮の完全性を調節または保存できる化合物 Pending JP2013543491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
PCT/DK2011/050375 WO2012041334A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Publications (2)

Publication Number Publication Date
JP2013543491A JP2013543491A (ja) 2013-12-05
JP2013543491A5 true JP2013543491A5 (enExample) 2014-06-05

Family

ID=44872128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530571A Pending JP2013543491A (ja) 2010-10-01 2011-09-30 急性外傷性凝固障害及び蘇生した心停止の予防または処置に使用するための血管内皮の完全性を調節または保存できる化合物

Country Status (9)

Country Link
US (1) US20130261177A1 (enExample)
EP (1) EP2622354A1 (enExample)
JP (1) JP2013543491A (enExample)
KR (1) KR20140025303A (enExample)
CN (2) CN103238070B (enExample)
AU (1) AU2011307494B2 (enExample)
BR (1) BR112013007849A2 (enExample)
CA (1) CA2812846A1 (enExample)
WO (1) WO2012041334A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
US20140044797A1 (en) * 2011-04-19 2014-02-13 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
US20150057325A1 (en) * 2012-03-30 2015-02-26 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3068752A1 (en) 2013-11-13 2016-09-21 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog
EP3215634B1 (en) 2014-11-06 2021-08-04 The Regents of the University of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN107430136A (zh) * 2015-02-03 2017-12-01 科罗拉多州立大学董事会,公司实体 粘弹性分析用于预测大量出血的用途
DK3278112T3 (da) * 2015-03-29 2021-12-13 Endothel Pharma Aps Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11169142B2 (en) 2016-05-11 2021-11-09 The Regents Of The University Of Colorado, A Body Corporate Viscoelastic analysis in patients with disease associated with cardiovascular system
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
US12105099B2 (en) * 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
AU4405293A (en) * 1992-06-05 1994-01-04 Barbara M. Alving Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
WO2011089152A1 (en) * 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity

Similar Documents

Publication Publication Date Title
JP2013543491A5 (enExample)
Yin et al. Efficacy and tolerability of sufentanil, dexmedetomidine, or ketamine added to propofol-based sedation for gastrointestinal endoscopy in elderly patients: a prospective, randomized, controlled trial
JP2013522212A5 (enExample)
FI3645002T3 (fi) Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
JP2016512564A5 (enExample)
FI3626270T3 (fi) Sydän- ja verisuonitautien hoito
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2016516016A5 (enExample)
NZ598534A (en) Dosage regimen of an s1p receptor modulator
Lee et al. Cardiorespiratory and anesthetic effects produced by the combination of butorphanol, medetomidine and alfaxalone administered intramuscularly in Beagle dogs
JP2016527202A5 (enExample)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2012502103A5 (enExample)
JP2018531605A5 (enExample)
Amin et al. Comparative study of neuromuscular blocking and hemodynamic effects of rocuronium and cisatracurium under sevoflurane or total intravenous anesthesia
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2016520114A5 (enExample)
JP2016510040A5 (enExample)
FI3590960T3 (fi) Perifeeristen hermojen IgG-stimuloitu remyelinaatio
JP2023020885A5 (enExample)
JP2015512923A5 (enExample)
CN103655549B (zh) Myrtucommuacetalone在治疗或预防急性心衰药物中的应用
Ayatollahi et al. Comparison of effects of ephedrine, lidocaine and ketamine with placebo on injection pain, hypotension and bradycardia due to propofol injection: a randomized placebo controlled clinical trial
CN103520161B (zh) 一种解决长效酰胺类局麻药所致心脏停搏的药物组合
CN103356677B (zh) Houttuynoid D在制备治疗或预防急性心衰的药物中的应用